Physician profile
Laura Rosenberg
NPI 1912197005
$7,733.93
in general payments reported to CMS, 2019-2025
37 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $108 · 2021: $390 · 2022: $1,090 · 2023: $1,646 · 2024: $2,073 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,669 · Education: $28.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,669.19 |
| Education | $28.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,226.58 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $969.50 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $575.83 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $534.74 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $438.56 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $410.01 | 2023-2025 | Omvoh |
| Genzyme Corporation | $361.86 | 2022-2025 | |
| Pfizer INC. | $355.96 | 2019-2025 | |
| Qol Medical, LLC | $224.26 | 2021-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $194.17 | 2022 | |
| Madrigal Pharmaceuticals | $188.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $180.93 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $162.32 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $97.47 | 2021-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $73.77 | 2019-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $69.44 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $68.01 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $62.82 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Gilead Sciences, INC. | $57.01 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.32 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $51.07 | 2023-2024 | Dificid, Zinplava |
| Organon LLC | $49.27 | 2021-2023 | Renflexis, Hadlima |
| Laborie Medical Technologies Corp. | $42.46 | 2023 | |
| Lucid Diagnostics INC. | $31.78 | 2023 | |
| Ironwood Pharmaceuticals, INC | $29.08 | 2020-2024 | |
| Celltrion USA INC. | $28.07 | 2023 | Yuflyma |
| Medtronic, INC. | $27.36 | 2024 | Interstim |
| Nestle Healthcare Nutrition INC. | $20.22 | 2023 | |
| Braintree Laboratories, INC. | $19.94 | 2021 | |
| Capsovision, INC. | $19.67 | 2023 | Capsocam Plus |
| Ucb, INC. | $19.10 | 2019 | |
| Novo Nordisk INC | $18.31 | 2025 | Wegovy |
| Shionogi INC | $15.83 | 2019 | |
| Albireo Pharma, INC. | $15.36 | 2023 | Bylvay |
| Ethicon US, LLC | $15.08 | 2020 | |
| Allergan, INC. | $11.76 | 2020 | |
| Daiichi Sankyo INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.